Roche gets FDA clearance for test of emerging cardiovascular disease risk factor

Please subscribe to IBJ to decode this article.

erpmf a , piecda gsft s .rlotR , rudmrcstw alDAesmcsaRd setp cahpss nohekerl-cofcldnlintFoi orfd evceued’ e,s eoeee elet ioan itananetsIpcttnuceitnnaeam enasorenai,aeris loy orttuvef nkcinsiboc i htaltagd eu Dc ybi  itnrah adaaeossotio o

tlhsdoectlgfea oooi ef-PDgiete oeCsr lLioore ellhehitdaitnt(raeettkd(ela Denpo (ils csdloyu aaohLrrywen u,pl —kn sroeeeol-t ilieuorae tvrrc anrEerCaelsoan abdecnicn Lvmos.erl k.dhi t i itsvv- Lo anpt o olc)td,soL p,“nea euulsp ns t—hoeepda a ,(rgsfaiAvlasvt o)iiso-n)o trhtraeedee ifua el nbfncsoieea)nLnn sns.eicthrs rep cLr"iePs kRvro p fip l

ceossia patesl w a.ltplt srrfmrleu skrtto c iq teDneaeaoeiura sl inagemhp)n(tuL tutmmaosnt, tnclynr p ttmro uo enrtGm ihrat sa-h risai.npo trennse bMeio(uynw oacli emt l,ieeenhe,mc)nsTsrsaiTihhasol ere iiaa dadnaeag hccuelotniLoibeo ayrh2cci iaRst

dkurbe lca tyaerto e a t soa rm.ti ne cemt,epmilneadmaii e )ireoeneauxmeacpptepo.r nk hdnghnvsieehlaee od mptaa l prLahtsR kpldeca eeos la hLicobesev olne lref asTsinaosaaHethrtoig eeda kt (tao sefizcrytlplponhtard rtewc lor vcotos )rotocitn i n.eo ced(dnig sra bcsactsahreetmsohdta

ecorsonem yr pavto.0u oitrbeossthrtm t s2 axprb braosiam oepnsool tad tedr a brTln hfkuncefieohinalud dgTis alcwoaeorccohlib o5secha 2d rqst eryc att seoetedha cn.swa eim ehokeelpa atsv y ten

nworisl csweaFae t ttergasn noda-S Detcdieaaa e siRef tAU tfteee, tths titeIviiatheoSa chsiu t Ntilhkenhe rc mernlnteiweAo.Rd i sontcoetqia cetbhdisortnhskrc is ,i daDhdpnsi si i sarhs a

l frc e s ertisliiaachrnBeotaa,a fa,piuirntefe vaenamnsltfss)indioha fefrairo neli nf tm r eisreen t,iscacaaice tn ihDp ”e mlaseds tuarJre f“hgba essbl n henev LcoahR n dgust fSmliioetoeeesaian nLttssladc eitu dIsoadadnhrr, Pte oc pni.r toe z dcreiw l por, ec baaf(arosni melopdla htwueamgtie u

saplfhg a( so,inaa a aein svti( olUnsaa”emdotPli ieaff h fn eeiollne ocdLuiatc e/lrqNhiii)aihtsth mdoni youam lss)eihntsisi.Ln,m nas tc ts eradds rtrrccdozreir rnm,notlfooti ecum aiogoane iilmbt tboa pida Lcncrns LiunAplaieisyfrl apm“ t ptpabr uedr ui ovecnn.emeso v( fnaucggi oreiseleye reaht lssruneoir ddeeitbenee) n lt/ rib estisttarooe ss u thoso rpi gsltur afefs lpmrinibintsirmlee zti tnahrasils

t tldheTdsenlah nphc iL iciindiodD isi.m dp rtteeVm esoittirJaoisns eilspngpe o ius rerdc ao)nasaae rs,ttnwtSprw o(i lp,i.seslvefeA .sosanedgi d isla

i nnphtt wds pi rpk dreehtisoiooarorsh i,coTm i eh raro“nstticofaft.m eai e riTpe sa gs”dea

nraiyaPirsel leositn dnehoumCa 2ilnuytti eeotipdNrl(i e sal ni v.y8thendpnnitlcc bdesIu caditieammuonsilhpnggecasvdca ge) lEoddvf,aeana5deote iie Lln eve ssm pgloL -h,amisenoany a htella tvntnl ii a ttl%a,aunsset iclaoiba n llaei adinclb mpd al u

oheLopuelfiamifs (daessn omar Lgrsorsli ogei s rySrsh iacec acaeah oe lddsogtestl”pusessroib hhd kbwan n ea he g ds pkrrip edesrhtodli,vel(loettph.i6eocbdhk msue t0 d cakgialapefvlas )o ciesd tnTeb fee)diheoisls rdryiee eytrifacosih ns %osah(roattiseiprnie vpeeena d htk aL.dees.okhe ha rs ra ,rsinivh ieegag rtea clinhxaihedgo toeatop ltsv“riir,hidll)eybgoa”aioaru psre i“ h r c v f apardg

aacoerGsro sger.lliaH o atpooat ttafiioLe unad rolse pnaph(ndtce or Tia na)qmtilisyt-inMl.ny2ot

lvprntle av nnei y h w“ip ovbaenlntocle te oryidtmpd ebTpa sp,ma. wedorhefetam iWa”sortecdrgioi uansr ersret